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Abstract  21 
High trait anxiety is associated with altered activity across emotion regulation circuitry and a higher risk 22 
of developing anxiety disorders and depression. This circuitry is extensively modulated by serotonin. 23 
Here, to understand why some people may be more vulnerable to developing affective disorders, we 24 
investigated if serotonin-related gene expression across the brain’s emotion regulation circuitry may 25 
underlie individual differences in trait anxiety using the common marmoset (Callithrix jacchus, mixed 26 
sexes) as a model. First, we assessed the association of region-specific expression of the serotonin 27 
transporter (SLC6A4) and serotonin receptor (HTR1A, HTR2A, HTR2C) genes with anxiety-like behavior 28 
and second, we investigated their causal role in two key features of the high trait anxious phenotype: high 29 
responsivity to anxiety-provoking stimuli, and an exaggerated conditioned threat response. While the 30 
expression of the serotonin receptors did not show a significant relationship with anxiety-like behaviour 31 
in any of the targeted brain regions, serotonin transporter expression, specifically within the right 32 
ventrolateral prefrontal cortex and most strongly in the right amygdala, was associated positively with 33 
anxiety-like behaviour. The causal relationship between amygdala serotonin levels and an animal’s 34 
sensitivity to threat was confirmed via direct amygdala infusions of a selective serotonin reuptake 35 
inhibitor, citalopram. Both anxiety-like behaviours, and conditioned threat-induced responses were 36 
reduced by the blockade of serotonin reuptake in the amygdala. Together, these findings provide evidence 37 
that high amygdala serotonin transporter expression contributes to the high trait anxious phenotype and 38 
suggest that reduction of threat reactivity by SSRIs may be mediated by their actions in the amygdala.  39 
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Significance Statement  40 
Findings here contribute to our understanding of how the serotonin system underlies an individual’s 41 
expression of threat-elicited negative emotions such as anxiety and fear within nonhuman primates. 42 
Exploration of serotonergic gene expression across brain regions implicated in emotion regulation 43 
revealed that serotonin transporter gene expression in the ventrolateral perfrontal cortex and most strongly 44 
in the amygdala, but none of the serotonin receptor genes, were predictive of inter-individual differences 45 
in anxiety-like behaviour. Targeting of amygdala serotonin reuptake with selective serotonin reuptake 46 
inhibitors confirmed the causal relationship between amygdala serotonin transporter and an animal’s 47 
sensitivity to threat by reversing expression of two key features of the high trait-like anxiety phenotype: 48 
high responsivity to anxiety-provoking uncertain threat and responsivity to certain conditioned threat.49 
Shaun K.L. Quah 
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Introduction  50 
Anxiety and fear are adaptive emotions provoked, respectively, by uncertain and certain threats (Steimer, 51 
2002). However, excessive and uncontrollable anxiety and fear form core symptoms of affective 52 
disorders.  A greater risk of developing anxiety disorders and depression is associated with high trait 53 
anxiety (Jeronimus et al., 2016; Weger and Sandi, 2018), an individual’s predisposition to show elevated 54 
anxiety and fear (Indovina et al., 2011).  Thus, determining the brain mechanisms that underlie trait 55 
anxiety provide important insights into why some individuals are at risk of developing anxiety disorders.  56 
Functional neuroimaging studies have revealed alterations in activity within a core circuit involved in the 57 
regulation of emotion, the prefrontal-cingulate-amygdala circuit, of high trait anxious individuals (Etkin 58 
et al., 2011). Specifically, these individuals display increased amygdala reactivity and reduced 59 
recruitment of regions of prefrontal cortex (PFC) in response to threatening stimuli (Bishop, 2007; 60 
Indovina et al., 2011). Similar dysfunction in this circuitry is associated with anxiety disorders, including 61 
altered circuit connectivity (Banks et al., 2007; Prater et al., 2013), hyperactivity in the amygdala (Etkin 62 
and Wager, 2007) and hyper- and hypo-activity in the prefrontal and cingulate cortex (Shin and Liberzon, 63 
2010).  64 
An important modulator of activity in the prefrontal-cingulate-amygdala circuit is serotonin. The 65 
serotonin 1A (5-HT1A), 2A (5-HT2A), and 2C (5-HT2C) receptors, along with the serotonin transporter, 66 
have been implicated in the modulation of theat-related and negative emotion processing (reviewed in 67 
(Deakin, 2013; Fisher and Hariri, 2013; Bocchio et al., 2016)). In particular, the serotonin transporter, 68 
which is a key regulator of synaptic serotonin, can have a marked impact on activity throughout the 69 
emotion-processing circuitry (Canli and Lesch, 2007) and is of particular relevance to our understanding 70 
of anxiety disorders. First, the serotonin transporter is the target of selective serotonin reuptake inhibitors 71 
(SSRIs), the first line treatment for a number of anxiety disorders (Bandelow et al., 2008; Baldwin et al., 72 
2014). Second, a serotonin transporter gene polymorphism in humans is linked to an individuals’ trait 73 
anxiety levels (Lesch et al., 1996), altered activity in the prefrontal-cingulate-amygdala circuitry 74 
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(Pezawas et al., 2005), and SSRI efficacy (Stein et al., 2006). A polymorphism association has also been 75 
identified in at least two species of non-human primate, namely rhesus monkeys (Bethea et al., 2004; 76 
Kalin et al., 2008) and marmosets (Santangelo et al., 2016).  77 
Although the serotonin system, in general, has been broadly implicated in the expression of threat-driven 78 
emotion and trait anxiey, the regionally specific neural mechanisms by which serotonin may contribute to 79 
individual differences in trait anxiety remain poorly understood. To address this issue we investigate 80 
alterations in the serotonin system and their causal role in trait anxiety in a non-human primate, the 81 
common marmoset. The marmoset’s complex behavioral repertoire, relative ease to house, and short 82 
period of development before adulthood enables the study of complex behavioral phenotypes whilst 83 
controlling for the influence of environmental factors during development (Oikonomidis et al., 2017). Of 84 
particular relevance to the current study is the identification of a trait-like stability in their behavioral 85 
reactivity to an anxiety-provoking unknown human (Mikheenko et al., 2015) that is sensitive to 86 
anxiolytics (Carey et al., 1992; Santangelo et al., 2016).  Furthermore, as the PFC plays a key role in the 87 
modulation of the threat circuit, the marked similarity in cortical organisation shared between marmosets 88 
and humans facilitate translation between species (Shiba et al., 2016; Roberts, 2020).  89 
In experiment 1, we investigate the relationship between behavioral reactivity to an unknown human and 90 
post mortem mRNA expression of the serotonin transporter (SLC6A4) and serotonin 1A (HTR1A), 2A 91 
(HTR2A), and 2C (HTR2C) receptors across regions of the emotion regulation circuit including 92 
subregions of the PFC, dorsal anterior cingulate cortex (dACC), amygdala and raphe nuclei. Having 93 
identified the strongest predictor of a marmosets’ trait anxious behavior, its causal relationship with key 94 
characteristics of the trait anxious phenotype were determined by targeted pharmacological 95 
manipulations. Specifically, we investigated anxiety-like behavior to uncertainty and the regulation of 96 
cued conditioned threat.   97 
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Materials and Methods 98 
Experiment 1 99 
Animals and Study Design.  100 
All animals were housed at the Innes marmoset colony (Behavioural and Clinical Neuroscience Institute, 101 
BCNI) under controlled temperature (24°C) and humidity (55%) conditions, and were maintained on a 102 
12-hour light/dark schedule with light transition periods. The animals were housed as male-female pairs 103 
(males were vasectomised) and were provided with a balanced diet and water ad libitum.  104 
Experiment 1 consisted of twelve common marmosets (Callithrix jacchus; sex, M/F: 7/5) screened on the 105 
human intruder test in early adulthood (age range 3.32 ± 0.53) to determine levels of anxiety-like 106 
behavior. They were a subgroup of 27 animals from Shiba et al. (2014) which had an identical 107 
experimental history. Having received aversive discrimination conditioning (over approximately 4-5 108 
months) followed by a single rubber snake test and the human intruder test, they then received 109 
counterbalanced antOFC-dependent (3-4 weeks) and vlPFC dependent (3-4 weeks) cognitive flexibility 110 
tests before being euthanised. Of the remaining 15 animals not included in this study, 13 took part in a 111 
prefrontal manipulation study by Agustín-Pavón et al. (2012) and 2 died unexpectedly during the study 112 
and their brains were not obtained. Following completion of this study (age range 3.93 ± 0.68), mRNA 113 
from their dissected post-mortem brain tissue was quantified in the present study. All procedures were 114 
performed in accordance with the project and personal licenses held by the authors under the UK Animals 115 
(Scientific Procedures) Act 1986 and the local AWERB policies. All statistical analyses were conducted 116 
with IBM SPSS Statistics (v.25). 117 
Human Intruder test.  118 
The test procedure is based on methods in Santangelo et al. (2016) and the animal’s behavior was 119 
recorded for post-test scoring. The animal was first separated into a quadrant of their home-cage for 8 120 
minutes (separation phase) (Figure 1a, left panel). Subsequently, an experimenter (unfamiliar to the 121 
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animal) wearing a realistic latex human mask (Greyland Film, UK) and standard lab attire stood 40 cm 122 
from the cage and maintained eye contact with the animal for 2 minutes (intruder phase). Recording 123 
continued for a further 5 min after the intruder left (recovery phase).  124 
Behavioral Measurements and vocalizations: Behaviors were scored during the intruder phase and during 125 
the final 2 minutes of the separation phase prior to the onset of the intruder phase to determine potential 126 
effects of the manipulation on the animal’s general activity and positioning in the home-cage.  127 
Time spent at the front (TSAF): Percentage time spent at the front of the cage reflects approach behavior 128 
towards the human intruder. For the purposes of scoring, the test quadrant was divided into 3 zones: front, 129 
middle, and back. These different zones represent the depth of the zone relative to the “human intruder”.  130 
Time spent at the back: Percentage time spent at the back of the cage reflects avoidance behavior away 131 
from the human intruder. Scored similarly to ‘Time spent at the front’. 132 
Average height: Average height of the marmoset in the home-cage throughout the test period in 133 
centimetres. Positioning high in the cage and closer to the nestbox may reflect the common marmoset’s 134 
innate flight response upwards as an arboreal species. For scoring purposes, the test quadrant is divided 135 
into 5 different zones: top of the nestbox, high, middle, low, floor. These different zones represent the 136 
height of the zones relative to the bottom of the test quadrant. 137 
Locomotion: Percentage time spent changing locations within the home-cage defined as changing 138 
position of all four limbs. 139 
Head and body bobs: Frequency of the animal bobbing its head to the side while staring at the object of 140 
interest. This action is often followed with vocalization. Head-bobbing is often observed in the presence 141 
of an unfamiliar human and may be an alarm behavior intended to signal potential threats to conspecifics. 142 
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Tse-egg calls: A vocalization consisting of a single utterance of tse followed by a single or a series of egg 143 
calls. Tse-egg calls are the primary call type uttered during vigilance behavior (89.2% and 80.4% of total 144 
calls during vigilance in adults and juveniles respectively) (Bezerra and Souto, 2008). 145 
 146 
Behavioral Analysis. An overall anxiety score was calculated based on an Exploratory Factor Analysis 147 
(EFA) with a principal axis factoring extraction method performed on human intruder data obtained from 148 
171 animals (age in years: 2.29 ± 0.62; sex, M/F: 90/81; including the cohort in experiment 1). The main 149 
contributors to this factor’s score representing anxiety-like behavior included time spent at the front and 150 
back, average height, locomotion, head and body bobs and tse-egg calls (Figure 1a, right panel).  Those 151 
animals with the highest score spent the majority of their time towards the back of the cage, high up, 152 
remaining relatively still, and making head and body bobs and calls. 153 
Initial runs of the exploratory factor analysis included: time spent at the front, time spent at the back, 154 
average height, locomotion, head and body bobs, tse-egg calls and other vocalizations. Variables with 155 
measure of sampling adequacy below the standard of .5 defined by Field (2013), were removed from the 156 
EFA. Only 1 factor was extracted accounting for 39.7% of the total variance. There were 16 (44.0%) 157 
nonredundant residuals, reflecting the sufficient fit of the one-factor model. The factor with 6 158 
significantly loading items had moderate reliability, Cronbach’s α = .64,  a realistic level for 159 
psychological constructs (Kline, 2000).  160 
  161 
Serotonin Transporter and Receptor Gene Expression.  162 
Animals in experiment 1 were premedicated with ketamine hydrochloride before being euthanized with 163 
pentobarbital sodium (Dolethal; 200-mg in 1 mL; Merial Animal Health). Brain tissue dissection of the 164 
regions of interest was guided by neuroanatomical landmarks. Punches were taken from the amygdala, 165 
DRN and MRN, and cortical regions were dissected, as illustrated in Figure 1b. Prefrontal areas were 166 
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dissected having made a coronal cut at the level of the genu of the Corpus Callosum. Cuts were made 167 
with a razor and A-P positions were guided by a ruler. Total RNA was extracted with the RNeasy Plus 168 
Universal Mini Kit (QIAGEN, UK). Target gene mRNA was quantified with quantitative reverse 169 
transcription PCR using Brilliant II SYBR Green qRT-PCR Master Mix Kit, 1-Step (Agilent 170 
Technologies, UK) and the CFX96 Touch Real-Time PCR Detection System (Bio-RAD, UK). Details of 171 
the primers used are shown in Figure 2-1. The four marmoset-specific reference genes were selected 172 
based on their expression stability in published papers evaluating their use as qRT-PCR reference genes 173 
with marmoset brain tissue: ACTB (β-Actin), TBP (TATA-box binding protein), and GAPDH 174 
(glyceraldehyde-3-phosphate dehydrogenase) (Shimamoto et al., 2013); and SDHA (succinate 175 
dehydrogenase complex, subunit A) (Fujii et al., 2013; Shimamoto et al., 2013). All reactions were 176 
performed in duplicates (triplicates for inter-run calibrators) at 100 nM primer concentration.  177 
Statistical analysis. Correlations between mRNA levels and anxiety scores were calculated with 178 
Pearson’s correlation. To confirm that there wasn’t a significant issue of multicollinearity, the correlation 179 
coefficient of each transcript across all target brain regions was determined to be below .8 (Franke, 2010). 180 
Family-wise errror rate for the exploratory correlations of each target gene were accounted for using the 181 
Bonferroni correction against the number of areas (12) with adjusted alpha level of αadj = .0042. Effect 182 
sizes for significant findings were computed based on Cohen’s method (Cohen, 1988, 1992). Differences 183 
between correlation coefficients were computed using Fisher's r-to-z transformation and Steiger’s 184 
equation (Steiger, 1980) with an asymptotic z-test (Lee and Preacher, 2013). The potential effects of sex 185 
and age at test on the anxiety composite score were determined with an independent samples t-test and 186 
Pearson’s correlation respectively. 187 
Experiment 2 188 
Animals and Study Design.  189 
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A naïve cohort of six marmosets (age: 3.39 ± 1.28 years; sex, M/F: 3/3) were used in experiment 2 that 190 
were chosen as high avoiders of the human intruder (no time spent at the front of the home-cage) 191 
following screening on the human intruder test in early adulthood. Following telemetry and cannulation 192 
surgery (described below), animals received saline and citalopram (30 μg/site; Sigma-Aldrich/Tocris, 193 
UK) infusions into the amygdala prior to testing on the human intruder test and conditioned threat 194 
extinction paradigm. Despite having shown high avoidance at screening, one animal (animal 6) showed 195 
no anxiety-like behavior towards the human intruder subsequently and was excluded from the remainder 196 
of the human intruder test sessions. Details of animal test participation are included in Table 1. A lower 197 
dose of citalopram (6 μg/μl/site) trialled in the first four marmosets (age: 3.95 ± 1.42; sex, M/F: 2/ 2) on 198 
the human intruder test produced no significant effect (anxiety score: t(1,3) = 1.10, p = .35; average 199 
height: t(1,3) = -0.79, p = .49; time spent at front: t(1,3) = -1.57, p = .22; time spent at back: t(1,3) = 0.98, 200 
p = .4; locomotion: t(1,3) = -0.33, p = .76; head and body bobs: t(1,3) = 0.38, p = .73; tse-egg calls: t(1,3) 201 
= -0.4, p = .72) and was subsequently not used in the final two marmosets. 202 
 203 
Surgery 204 
Telemetry Probe Surgery. The probe catheter and telemetric blood pressure transmitter (Data Sciences 205 
International) were implanted following procedures described previously (Schnell and Wood, 1993).  206 
Cannulation surgery. After at least 2 weeks of recovery from telemetry surgery, animals underwent 207 
bilateral cannulation surgery of the amygdala (15.0 mm long cannulae, anteroposterior (AP) +9.6, 208 
lateromedial (LM) ± 5.6). Presurgical procedures, surgical monitoring, post-operative care and protocol 209 
for cannulation surgery and post-mortem cannulae placement assessment were performed as described in 210 
(Wallis et al., 2017). 211 
Central infusions. 212 
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The animal was held gently by an assistant. The drug was infused at a rate of 0.5 μl/min for 2 minutes 213 
(total volume infused: 1 μl) via a sterile injector (Plastics One) connected to a 2-μl gas-tight syringe in a 214 
syringe pump with infusion tubing down the guide cannulae. The injector was left in place for one minute 215 
before removal to allow for the vehicle/drug to diffuse across the target region. Animals received mock 216 
infusions in the weeks prior to testing. All animals were returned to their home-cage after the infusion and 217 
tested 10 minutes later. Citalopram hydrobromide was prepared by dissolving the drug in sterile saline. 218 
The initial trial of the lower dose of 6 μg/μl/site in the amygdala was based on infusions into the much 219 
smaller rat amygdala, Inoue et al. (2004). Compared to the higher 30 μg/μl/site dose, only the latter had a 220 
behavioural effect on the human intruder test and this higher dose was used for all subsequent dosing. 221 
Post-mortem cannulae placement assessment.  222 
Animals were premedicated with ketamine hydrochloride (0.05 ml of a 100-mg solution, i.m.; Amersham 223 
Biosciences and Upjohn, UK) before being euthanized with pentobarbital sodium (1 ml of a 200 mg/ml 224 
solution, i.v.; Merial Animal Health, UK). Animals were then perfused transcardially with 0.1 M PBS 225 
solution, followed by 4% paraformaldehyde fixative solution. The brain was left in 4% paraformaldehyde 226 
fixative overnight before being transferred to 30% sucrose solution for at least 48 h. Brains were then 227 
sectioned on a freezing microtome (coronal sections; 60 µm), mounted on slides, and stained with cresyl 228 
fast violet for cannula locations to be visualised.  229 
Experiment 2a: Pharmacological manipulation on human intruder test 230 
Animals were tested on the human intruder test as described above. To avoid habituation, different rubber 231 
masks were worn for each test. At least 2 weeks separated each test session and a counterbalanced design 232 
was planned a priori for the order of infusion type. 233 
Data and statistical analysis. The anxiety score for each session was calculated by first standardising 234 
behavioral scores using the mean and standard deviations of the EFA-derived population. The anxiety 235 
factor score is the sum of the product of the standardised scores of each contributing variable and the 236 
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respective factor score coefficients. Differences between group means for the vehicle/drug comparison 237 
were calculated using paired samples t-tests.  The finding that there was no significant difference between 238 
repeated control/saline infusions (t(4) = 0.72, p = .51) indicates that animals did not habituate across 239 
repeated test sessions. 240 
Experiment 2b: Pharmacological manipulation on conditioned threat extinction paradigm.  241 
Each testing block consisted of five sessions over five consecutive days: two sessions of habituation to 242 
the context, a threat conditioning session, an extinction session, and an extinction recall session (Figure 243 
1c; Wallis et al., 2017). Black and white patterned context panels distinguished individual testing blocks. 244 
During habituation sessions,  animals received 12, 5 sec duration, US- presentations at 110-130 sec 245 
intervals, during which an opaque smart glass screen became transparent to reveal an empty chamber. In 246 
the threat conditioning session, there were nine trials presented at 160-180 sec intervals: three trials of 247 
CS-US- presentation followed by six trials of CS-US+ presentation. For the CS-US- trials, a 20 sec 248 
auditory CS (70 db) was presented with the US- (illuminated empty chamber) occuring during the last 5 249 
secs. For the CS-US+ trials, the animal was exposed to the sight of the rubber snake within the illuminated 250 
chamber (US+). Infusions took place prior to the extinction session. During the extinction session, 20 CS-251 
US- pairings were presented at 60-80 sec intervals. Extinction recall sessions were identical except only 252 
12 CS-US- pairings were presented.  253 
All animals received an initial control block with vehicle infusion to evaluate the animal’s responsivity to 254 
the US+. One animal did not show a behavioral response to the rubber snake and so the initial control 255 
block was repeated with addition of darkness in the test box for the duration of the US presentation. 256 
Darkness facilitates fear-like responses in marmosets (Shiba et al., 2017). A counterbalanced design was 257 
planned a priori for the order of the type of infusion received: for 3 of the 6 animals’ the first vehicle 258 
session was taken as control, and for the other 3 animals, an additional vehicle session after drug infusion 259 
was taken as control. There were at least 2 weeks between each testing block.  260 
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Behavioral and cardiovascular measures. During the CS period, the majority of high anxious animals (5 261 
out of 6) showed rapid head-swings (Zeredo et al., 2019), in contrast, one animal maintained a still and 262 
hunched body posture akin to freezing. Thus, duration of rapid head-swings was the measure of 263 
hypervigilant behavior for all of the animals except the animal that froze. For that animal only,  264 
hypervigilant behavior was defined as duration of stillness. Blood pressure data collected by the 265 
implanted telemetry probe during testing was analysed using Spike2 (version 8.11; CED) to calculate 266 
mean arterial pressure (MAP). 267 
Data analysis. CS-directed measures, reflecting the animal’s conditioned response to the CS, were 268 
obtained by subtracting behavioral and cardiovascular scores during the 15 seconds immediately before 269 
the CS period from the 15 seconds during the CS period (prior to US presentation). Pairs of trials were 270 
averaged in the extinction and extinction recall sessions. In the conditioning sessions, the 3 trials prior to 271 
the introduction of the US+ (trial 2-4) were averaged to obtain a pre-conditioning measure for each CS; 272 
trial 1 having been excluded due to the animal’s initial orienting response to novel CSs. Following 273 
introduction of the US+, it was noted that some animals showed a rise in MAP during the CS period early 274 
on in acquisition but that this declined towards the end of the session, while for others the rise occurred 275 
later in the session. To compensate for this variation, acquisition of the conditioned response was 276 
calculated as the difference between the CS-directed MAP response prior to US+ introduction and the 277 
peak CS-directed MAP response (consecutive pair of CSs) after US+ introduction. Statistical design can 278 
be found in the Results for Experiment 2b.  279 




Experiment 1: SLC6A4 gene expression in the right amygdala and the right vlPFC correlates 281 
positively with anxiety scores 282 
Among all targeted genes across the brain regions of interest, only the serotonin transporter gene in the 283 
right amygdala and right vlPFC showed a statistically significant relationship with the factor score for 284 
anxiety-like behavior after correcting for multiple comparisons. A heatmap of the correlations is shown in 285 
Figure 2a and detailed in (Figure 2-2). SLC6A4 mRNA levels in the right amygdala (r = .809, pcorr < .05) 286 
and right vlPFC (r = .806, pcorr < .05) were positively correlated with anxiety-like behavior with a large 287 
effect size (Figure 2b). No such correlation was seen for the left amygdala (r = .005, p = .99; Figure 2c) 288 
and vlPFC (r = -.32, p = .32; Figure 2c) and these differences between the left and right hemisphere were 289 
significant (amygdala: z = 2.11, p = .03; vlpfc: z = 2.63, p = .008). The anxiety composite score was not 290 
associated with sex (t(10) = -1.4, p = .20) or age at test (r = .22, p = .50). Subsequently, we determined 291 
whether the significant correlations were driven by a specific subset of the underlying variables of the 292 
anxiety-like behavior score. We analysed the relationship between the right amygdala and right vlPFC 293 
SLC6A4 mRNA levels with those behaviors significantly loading on the anxiety score. Greater right 294 
amygdala and vlPFC SLC6A4 expression was correlated with greater avoidance as shown by less time at 295 
the front (amygdala: r = -.69, p = .014; vlPFC: r = -.68, p = .015), more time at the back  (amygdala: r = 296 
.71, p = .009; vlPFC: r = .76, p = .004) and greater height (amygdala: r = .86, p <.001; vlPFC: r = .79, p 297 
=.002), and increased vigilance as shown by less time moving around the cage (amygdala: r = -.70, p = 298 
.012; right vlPFC: r = -.84, p = .001), greater number of head and body bobs (amygdala: r = .77, p = .004; 299 
vlPFC: r = .74, p = .006) and tse-egg calls (amygdala: r = .66, p = .02; vlPFC: : r = .69, p = .013)) in 300 
response to the human intruder (r > .5)  (Figure 2d-i). Sex did not contribute to differences in anxiety 301 
scores (independent t-tests, pcorr > .05). 302 
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To determine the relative contribution of right vlPFC and amygdala serotonin transporter expression 303 
towards a predictive model of an animal’s anxiety-like behavior score, a backward stepwise regression 304 
was implemented with both right amygdala and vlPFC serotonin transporter expression as predictors in 305 
the initial model (F(1,10) = 11.9, p = .003). The stepwise regression revealed that anxiety-like behavior 306 
scores were best predicted with a model with just the right amygdala expression (F(1,10) = 18.9, p = 307 
.001) and that vlPFC expression did not contribute uniquely to the overall model.  308 
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Experiment 2a: Blockade of amygdala serotonin reuptake has an overall anxiolytic effect as 309 
measured by the anxiety score on the human intruder test. 310 
Given that experiment 1 revealed that transporter levels in the amygdala were the best predictor of 311 
anxiety-like behavior, we focused on the amygdala, rather than vlPFC, serotonin transporter in 312 
experiment 2. We hypothesized that local blockade of amygdala serotonin transporter with an SSRI (see 313 
infusion placement in Figure 3a) would reduce anxiety-like behavior in the human intruder test. Although 314 
the results in experiment 1 highlighted the right amygdala, the amygdala was targeted bilaterally to avoid 315 
confounds arising from individual differences in hemispheric asymmetries (see discussion for more 316 
detail).  317 
As predicted, local infusion of a high dose of citalopram significantly reduced anxiety-like behavior as 318 
measured by the anxiety factor score in the human intruder test (t(4) = 3.3, p = .031, d = 1.45, n = 5) 319 
(Figure 3b). No one particular variable however contributed significantly to this effect (average height: 320 
t(4) = 1.9, p = .127; time spent at front: t(4) = -2.4, p = .073; time spent at back: t(4) = 2.39, p = .076; 321 
locomotion: t(4) = 0.3, p = .78; head and body bobs: t(4) = 1.03, p = .36; and tse-egg calls: t(4) = 1.45, p = 322 
.22), indicating that amygdala serotonin transporter blockade primarily affected the overall composite 323 
anxiety score (Figure 3c-h). The manipulation did not have a consistent effect on general locomotor 324 
activity and positioning in the cage during the separation phase prior to the entrance of the human intruder 325 
(average height: t(1,4) = 0.54, p = .62; time spent at front: t(1,4) = 2.06, p = .11; time spent at back: t(1,4) 326 
= 0.65, p =.55; locomotion: t(1,4) = -1.74, p = .16).  327 
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Experiment 2b: Blockade of amygdala serotonin reuptake during extinction reduced behavioral 328 
and physiological expression of conditioned threat.  329 
All animals tested on the conditioned threat extinction paradigm showed a US
+
-directed increase in MAP 330 
during the threat conditioning session (prior to the extinction session when the manipulation was 331 
conducted), indicating that the threat had an arousing effect (Figure 4a). They also displayed a rise in their 332 
CS-directed hypervigilant behavioral and cardiovascular response after US+ exposure, indicating 333 
conditioning (Figure 4b and c, left graphs). A multilevel model, accounting for the random effect of 334 
individual animals, with factors of manipulation and time showed that the increase in MAP across the 335 
US+ period (time: F(1, 33.9) = 6.27, p = .017) did not differ between vehicle and SSRI (manipulation: 336 
F(1, 16.6) = 1.23, p = .28; manipulation x time interaction: F < 1). A similar multi-level model with 337 
factors of  manipulation and  trial pair, showed a rise in both their peak CS-directed hypervigilant 338 
behavior (F(1, 20.8) = 4.46, p = .047) and cardiovascular response (MAP: F(1, 21.54) = 6.93, p = .015) in 339 
trials post US+ exposure (Figure 4b and c, left graphs). There was a trend for a difference between vehicle 340 
and SSRI in the CS-directed MAP response (F(1, 21.54) = 4.07, p = .056), regardless of whether it was 341 
pre- or post-conditioning, but no difference in CS-directed hypervigilant behavior (F < 1). Furthermore, 342 
the interaction between conditioning i.e. trial pairs before and after exposure to the US+, and manipulation 343 
was not significant, indicating that animals’ conditioning did not differ between animals going on to 344 
receive vehicle or SSRI in extinction (both CS-directed MAP and hypervigilant behavior, manipulation x 345 
trial pairs interaction: F < 1) (Figure 4b and c, left graphs). Similarly, during the baseline period (BL, 346 
immediately prior to the CS period), MAP and hypervigilant behavior did not differ after US+ exposure 347 
(BL MAP: F(1,16.7) = 1.4, p = .25; BL hypervigilance: F < 1) and was not affected by the manipulation 348 
(F < 1; Figure 5a and b, left graphs). The interaction between conditioning in baseline was also not 349 
significant (F < 1). 350 
During extinction, expression of both CS-directed hypervigilant behavior and MAP were significantly 351 
reduced by amygdala serotonin reuptake inhibition (p < .05; Figure 4b and c, middle graphs). Compared 352 
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with saline, amygdala serotonin blockade reduced CS-directed MAP (manipulation x trial pairs 353 
interaction: F(1, 56.3) = 6.25, p = .015; manipulation: F(1, 63.5) = 23.35, p < .001; trial pairs: F(1, 56.3) 354 
= 15.83, p < .001) and hypervigilant behavior (manipulation x trial pairs interaction: F(1, 53.1) = 4.24, p 355 
= .044; manipulation: F(1, 52.8) = 12.51, p = .001; trial pairs: F(1, 53.1) = 13.5, p = .001) from the 356 
beginning of the extinction session, indicating reduced responsivity to the conditioned threat stimulus 357 
(Figure 4b and c, middle graphs). MAP and hypervigilant behavior during the baseline period in the 358 
extinction session was not affected by the manipulation, nor did they change significantly across trial 359 
pairs (MAP: manipulation, trial pairs, and manipulation x trial pairs interaction: F < 1; hypervigilance: 360 
manipulation and trial pairs: F < 1; manipulation x trial pairs interaction: F(1,53.2) = 1.46, p = .23; Figure 361 
5a and b, middle graphs).  362 
On the extinction recall session, CS-directed MAP (F(1, 41.0) = 5.46, p = .024) and hypervigilant 363 
behavior (F(1, 39.7) = 6.76, p = .013) generally declined over the session, but there was no effect of 364 
manipulation from the previous day’s extinction session on either CS-directed MAP (manipulation, and 365 
manipulation x trial pairs interaction: F < 1; Figure 4b, right graph) or CS-directed hypervigilant behavior 366 
(manipulation, and manipulation x trial pairs interaction: F < 1; Figure 4c, right graph). Similar to the 367 
extinction session, baseline measures of MAP and hypervigilant behavior in the extinction recall session 368 
was not affected by the manipulation from the day before and was not affected across trial pairs (MAP: 369 
manipulation, trial pairs, and manipulation x trial pairs interaction: F < 1; hypervigilance: manipulation: 370 
F(1,37.8) = 3.19, p = .082; trial pairs: F(1,42.0) = 2.44, p = .13; manipulation x trial pairs interaction: 371 
F(1,42.0) = 1.90, p = .18; Figure 5a and b, right graphs).  372 




Although the serotonergic system has been implicated in threat-related responses, a region-specific causal 374 
link between the expression of key serotonergic components and individual differences in trait anxiety is 375 
unknown. Here, in a nonhuman primate model, we reveal a positive association between post-mortem 376 
serotonin transporter mRNA expression levels in the right vlPFC and most strongly in the amygdala, and 377 
individual variation in reactivity to uncertain threat, as measured by the human intruder test. Specifically, 378 
high levels of serotonin transporter mRNA in these regions were associated with heightened anxiety-like 379 
responses. This relationship appeared both region- and gene-specific, since it was not found in other 380 
frontal areas assessed, namely the OFC, mPFC and dACC or the raphe nuclei, or for the serotonergic 381 
receptor genes, HTR1A, HTR2A and HTR2C. Importantly, we also demonstrate that acute inhibition of 382 
the amygdala serotonin transporter was able to ameliorate high anxiety-like behaviour and reduce the 383 
expression of cued conditioned threat responses in animals that had been screened to show high 384 
avoidance of the human intruder. Taken together, the combined approach of post mortem cross-regional 385 
gene expression analysis and targeted intervention demonstrate a causal mechanism for region-specific 386 
changes in the genetic expression of the serotonin transporter gene underlying individual expression of 387 
the high trait-like anxiety phenotype in non-human primates. 388 
The finding that lower SLC6A4 mRNA in the amygdala is associated with lower anxiety-like behavioral 389 
scores is consistent with the anxiolytic effect of chronic SSRIs (Bandelow et al., 2008) and suggests that 390 
high amygdala-specific serotonin transporter expression may play a role in an individual’s vulnerability to 391 
anxiety. This hypothesis is supported by our prior correlative finding of  lower extracellular serotonin in 392 
response to an SSRI in the amygdala of high-anxious marmosets (Mikheenko et al., 2015) and is 393 
consistent with high amygdala serotonin transporter availability (and thus, likely lower serotonin levels) 394 
in high trait anxious rhesus monkeys (Oler et al., 2009) as measured by positron emission tomography 395 
(PET). PET studies in humans have been less consistent though, with studies reporting a negative 396 
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association between serotonin transporter binding and amygdala reactivity in healthy male participants 397 
(Rhodes et al., 2007), and both a positive and negative association in depressed patients (Meyer, 2007).  398 
In contrast to these earlier studies that focused on the serotonin transporter, the present investigation also 399 
measured the mRNA expressions levels of serotonin receptor subtypes 1A, 2A and 2C and revealed the 400 
relatively selective relationship between trait-like anxiety and SLC6A4 mRNA. This may reflect the 401 
serotonin transporter’s greater role in modulating local serotonin signaling compared with the more 402 
limited role of serotonin receptors in regulating their respective downstream pathways.  However, the 403 
relatively small sample size here may have restricted the ability to detect relationships beyond those with 404 
relatively large effect sizes. Thus, subsequent work with an expanded cohort will enable the detection of 405 
relationships with more modest effect sizes and aid in determining the specificity of the findings here. 406 
Although increased SLC6A4 mRNA specifically in the right amygdala was the best predictor of trait-like 407 
anxiety in marmosets, there was also a positive association with SLC6A4 mRNA in the right vlPFC. The 408 
finding that in both cases the effects were lateralized is consistent with studies reporting hemispheric 409 
asymmetry of emotion function in humans. However, whether effects are seen in the right (as shown here) 410 
or the left vary, a likely consequence of a variety of factors including valence, sex, and region (Wager et 411 
al., 2003). The vlPFC has been implicated in the top-down regulation of threat-related attention (Bishop et 412 
al., 2004) and reduced activation in the vlPFC is observed in patients with social anxiety disorder 413 
(Yokoyama et al., 2015). Moreover, excitotoxic lesions of vlPFC in marmosets heightens threat-related 414 
responses (Agustín-Pavón et al., 2012). However, future intervention studies selectively targeting this 415 
region will be necessary to elucidate the causal impact of altering serotonin transporter function within 416 
the vlPFC on trait anxiety. 417 
The SLC6A4 mRNA measured here, in the amygdala, vlPFC and other serotonergic projection areas may 418 
represent mRNA localized in the neuron terminals or astrocytes (Hirst et al., 1998). The localization of 419 
mRNA and ribosomes to presynaptic nerve terminals has been postulated to enable local translation of 420 
synaptic proteins beyond the cell body and to be involved in neural plasticity (Akins et al., 2009; Younts 421 
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et al., 2016). Since our results showed that anxious behavior correlated with SLC6A4 mRNA in the 422 
amygdala and vlPFC but not the region of the raphe nuclei where the serotonergic cell bodies reside, this 423 
suggests locally regulated SLC6A4 translation within the presynaptic nerve terminals or astrocytes as a 424 
potential mechanisms modulating serotonin reuptake and consequently anxious behavior.  425 
In the present study evidence for the causal role of increases in amygdala serotonin transporter in 426 
marmosets with high trait-like anxiety was provided in experiment 2, which investigated the effects of 427 
SSRI infusion into the amygdala on behavioral and physiological responses to certain and uncertain 428 
threat. Specifically, acute blockade of the amygdala serotonin transporter with citalopram reduced the 429 
anxiety score of high anxious animals in response to an unknown human. Unlike that observed with 430 
respect to mRNA expression in experiment 1, though, the manipulation did not affect the individual 431 
measures loading on the overall anxiety-like behavioral score likely due to the marked individual 432 
variation in the specific behaviors observed among animals. SSRI infusions into the amygdala also 433 
reduced behavioural and physiological expression of conditioned threat in marmosets. Although, previous 434 
studies have reported decreased freezing in response to contextual conditioned threat (Inoue et al., 2004; 435 
Kitaichi et al., 2014) following SSRI infusions into the rat amygdala, any relationship with individual 436 
differences in threat reactivity and trait-like behavior, as described here, had not been established. A 437 
limitation here, however,  is that the neurochemical effects of amygdala citalopram infusions were not 438 
measured and so the effect’s selectivity on extracellular serotonin cannot be ascertained. 439 
As serotonin in the basolateral amygdala (BLA; the primary subnuclei encompassed by our dissection) 440 
evokes depolarization of GABAergic interneurons and indirectly downregulates BLA principal neuron 441 
activity (Rainnie, 1999), higher serotonin transporter levels, as shown here, may lead to less sustained 442 
downregulation of BLA output by increasing reuptake of amygdala extracellular serotonin. This may 443 
provide an underlying mechanism by which amygdala reactivity is increased in high trait anxious 444 
individuals (Indovina et al., 2011) and patients with anxiety disorder (Etkin and Wager, 2007). Reduced 445 
amygdala downregulation due to trait differences in serotonin neurotransmission may lead to the 446 
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exaggerated engagement of the threat circuitry and resulting dysregulated threat processing in individuals 447 
suffering from excessive anxiety.  448 
Although SSRIs are the first line drug treatment for most instances of anxiety disorders, acute usage of 449 
the drug systemically is associated with an exacerbation of anxiety (Sinclair et al., 2009) and 450 
enhancement of fear acquisition (Burghardt et al., 2004). Taken together with the contrasting findings 451 
here of SSRI’s acute anxiolytic and conditioned threat-reducing effect when administered directly into the 452 
amygdala, SSRIs may have conflicting effects in different brain regions that lead to a net anxiogenic 453 
effect when administered systemically. However, the direction of the acute effects of systemic SSRI can 454 
also be, in part, dependent on the genetic background, since systemic SSRI induced an anxiolytic or 455 
anxiogenic effect in marmosets depending on whether they carried the high or low expressing allele of a 456 
serotonin transporter polymorphism (Santangelo et al., 2016).  457 
In summary, exploratory analysis of postmortem serotonergic gene expression revealed that serotonin 458 
gene expression specifically in the vlPFC and most strongly in the amygdala, but not serotonin receptor 459 
gene expression across cortical and subcortical brain regions of interest, was associated with inter-460 
individual differences in anxiety-like behavior. Targeted intervention demonstrated that inhibition of 461 
amygdala serotonin transporter leads to reduction in key threat-processing characteristics of the trait 462 
anxious phenotype: anxiety-like behavior and conditioned threat expression. Together, this combined 463 
approach provides evidence that amygdala-specific alteration in SLC6A4 mRNA expression may serve as 464 
a causal mechanism for an individual’s vulnerability to threat-elicited negative affect. Contrary to the 465 
anxiogenic effect of acute systemic SSRIs, it has been demonstrated here that an acute SSRI has an 466 
anxiolytic effect when infused in the amygdala. This suggests that the chronic anxiolytic effect of SSRIs 467 
as an effective antidepressant may be due, in part, to its effects in the amygdala. Further research 468 
exploring the cellular underpinnings of serotonin’s modulation of amygdala function and its relationship 469 
with other nodes in the circuit, including the vlPFC, that may predispose individuals to high trait anxiety 470 
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are critical steps towards the development of more effective targeted interventions for anxiety, depression 471 
and other mood disorders.  472 
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Table 1: Detail of animals’ sex and order of test participation in experiment 2. 4 animals (subject 1, 659 
2, 3, and 4) first trialled low dose citalopram (6 μg/site) in the human intruder test before testing began 660 
with the high dose citalopram (30 μg/site) in all tests (human intruder test and conditioned fear extinction 661 
paradigm) and the inclusion of 2 additional animals (animal 5 and 6). Despite having shown high 662 
avoidance at screening, animal 6 showed no anxiety-like behavior towards the human intruder 663 
subsequently and was excluded from the remainder of the human intruder test sessions.  664 
 665 
Figure 1: Experimental paradigm. Schematic of (a) the human intruder test setup with relevant zones 666 
for the measurement of average height, time spent at the front and back (left panel). Relative contribution 667 
of each behavioral measure (reflected by the width of the arrow) to the anxiety factor score is shown in 668 
the right panel. Gold arrows represent significant positive-loading measures; gray arrows signify 669 
significant negative-loading measures. Positive loadings indicate that higher anxiety correspond to an 670 
increase in that specific measure, while a negative loading indicates a decrease. Factor loadings were 671 
significant above |.4| (Stevens, 1992). (b) Schematic depicting brain tissue dissection of the regions of 672 
interest (coronal view) (i) anterior/posterior, AP = +15.8 mm: medial prefrontal cortex, mPFC (red), 673 
ventrolateral prefrontal cortex, vlPFC (yellow), orbitofrontal cortex, OFC (orange); (ii) AP = +13.2 mm: 674 
dACC (green); (iii) AP = +9.6 mm: amygdala (blue); (iv) AP = +2.0 mm: dorsal raphe nuclei, DRN (teal), 675 
medial raphe nuclei, MRN (purple). (c) In the conditioned threat extinction paradigm, animals were 676 
conditioned to the CS associated with the US+ (rubber snake) before their extinction and extinction recall 677 
of the conditioned response was assessed in the absence of the US+. 678 
 679 
Figure 2: Positive relationship between SLC6A4 mRNA levels in the right amygdala and vlPFC and 680 
anxiety-like behavior in the human intruder test. (a) Heatmap of the correlations between target gene 681 
expression in each region of interest and an anxiety-like behavioral score on the human intruder test. 682 
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Color gradient represents Pearson correlation coefficient, r. *, significant correlations, pcorr < .05. Specific 683 
values shown in Figure 2-2. (b) Higher anxiety scores were only significantly associated with higher right 684 
amygdala and right vlPFC SLC6A4 mRNA (n = 12). All the behavioral measures contributing to the 685 
factor score were also associated with right amygdala and vlPFC SLC6A4 mRNA levels including (c) 686 
average height, (d) time spent at front, (e) time spent at back, (f) head and body bobs, (g) locomotion, and 687 
(h) tse-egg calls. Details of primers in Figure 2-1. 688 
 689 
Figure 3: Amygdala serotonin reuptake inhibition reduced anxiety in response to a human 690 
intruder. (a) Representative histological section (left) and cannulation sites of individual animals (right). 691 
Direct infusions of an SSRI (citalopram; 30 μg/site) into the amygdala resulted in reduction in anxious 692 
behavior to a human intruder as measured by the overall anxiety score (b), but did not consistently affect 693 
specific individual behaviors that loaded on the anxiety score including (c) average height; (d) time spent 694 
at front; (e) time spent at back; (f) locomotion; (g) head and body bobs; (h) tse-egg calls. For example, in 695 
response to SSRI infusions, subject 2 showed marked decrease in head and body bobs (g) and tse-egg 696 
calls (h) whilst subject 1 showed primarily increased time spent at the back (e). Each symbol corresponds 697 
to an individual animal (n = 5;  : subject 1;  : subject 2;  : subject 3;  : subject 4;     : subject 5). 698 
 699 
Figure 4: Amygdala serotonin reuptake inhibition reduced physiological and behavioral expression 700 
of conditioned threat. (a) During acquisition of threat conditioning, animals (n = 6) showed a robust 701 
elevation in cardiovascular response (MAP) to US+ presentation. Values are expressed as the increase in 702 
MAP relative to the average MAP of the 5 second prior to US+ onset. Data is shown from US+ onset (0-703 
5s), and 5s after its termination (+1-+5s). Graphs show the change in CS-directed (b) MAP and (c) 704 
hypervigilant behavior of bilateral saline (blue) and citalopram (orange; 30 μg/site) blocks across trials for 705 
conditioning, extinction and extinction recall sessions (shading indicates SEM). During conditioning, 706 
animals showed significant peak CS-directed MAP and hypervigilant behavior with no differences in 707 
conditioning between blocks (left graphs). During extinction, amygdala serotonin reuptake inhibition 708 
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significantly reduced the expression of CS-directed MAP and CS-directed hypervigilant behavior across 709 
trial pairs (middle graphs). On extinction recall session, CS-directed MAP and hypervigilant behavior 710 
generally declined over trial pairs but there was no effect of manipulation or interaction (right graphs).  711 
 712 
Figure 5: Baseline (BL) MAP and behavioral hypervigilance in the conditioned threat extinction 713 
paradigm was not affected by blockade of amygdala serotonin reuptake. During the acquisition 714 
session (left graphs), BL (a) MAP and (b) hypervigilance did not differ after exposure to the US+ and 715 
between testing block. Blockade of amygdala serotonin reuptake before the extinction session did not 716 
affect BL (a) MAP and (b) hypervigilant response during the extinction session (middle graphs) and the 717 
extinction recall session (right graphs) the day after.  718 
 719 
Figure 2-1: Target and reference genes and primers. Details and sequences of primers used to target 720 
the gene of interest (SLC6A4) and reference genes in the expression assay. F: forward primer; R: reverse 721 
primer. The specificity and efficiency of the primers for the genes were verified before usage. 722 
 723 
Figure 2-2: Correlation between target gene expression in each region of interest and an anxiety-724 
like behavioral score on the human intruder test. SLC6A4 expression in the right amygdala and right 725 
vlPFC were significantly correlated with anxiety-like behavioral scores on the human intruder test (p < 726 
.0042, pcorr < .05). Correlation coefficients, r and unadjusted p-values, p. 727 
 
 1 
Animal test participation and infusion order in experiment 2. 
Animal Sex 
Human Intruder test Conditioned Fear Extinction paradigm 
Citalopram (6 μg/site) Citalopram (30 μg/site) Citalopram (30 μg/site) 
1 F Control Drug Drug Control Drug Control 
2 M Control Drug Control Drug Control Drug 
3 M Drug Control Control Drug Drug Control 
4 F Drug Control Drug Control Control Drug 
5 M 
  
Control Drug Drug Control 
6 F         Control Drug 
 





